Ruxolitinib (Jakafi) plus PIM and CDK4/6 Inhibitors
First in ASH 2016 Series
by David Wallace
Dr. Raajit Rampal from Memorial Sloan Kettering Cancer Center in New York City, presented pre-clinical data from a trial of a three drug combination in animal models in MPNs. The combination of ruxolitinib, PIM447 ( a drug that targets PIM kinases) and LEE011 (a drug that targets the cell cycle by inhibiting CDK4/6) was effective at suppressing the growth of JAK2 mutant cells in vitro and in vivo. The treatment reduced the allele burden somewhat and prevented the development of fibrosis. The three-drug combo is currently being evaluated in a Phase 1 study.